Skip to content
Women’s Health Initiative

Women’s Health Initiative

Hero Swoop Purple 01

Women’s Health Initiative

Targeted Research. Coordinated Action. Better Health for All. 

The Current State: From high blood pressure, to depression, to autoimmune conditions, women are suffering at higher rates from many illnesses and diseases. Furthermore, exclusion of women from clinical trials and a lack of organized capital have hampered our understanding of any sex-based variation in diseases that present across genders [1,2].


The Challenge: This has resulted in a general underrepresentation and lack of focus on women’s health. Not understanding and studying these nuances impacts not only patients, but also employers and the healthcare system.

The application period will run from Aug. 5 – Nov. 21, 2025 at 1 p.m. EST.

Funding Inequities in Women's Health Research

Funding for conditions that predominantly affect women is insufficient. However, increasing investment could lead to significant benefits. Use the buttons below to explore the data. For the best experience, we recommend viewing this on larger screens, such as desktops.

Women are
50-75%
more likely than men to have an adverse drug reaction across all therapeutic indications [3].

80%
of drugs that have been pulled from the market over safety concerns are due to adverse effects specifically in women.

Working Toward Solutions

While some progress has been made, from increased female participation in clinical trials to women’s health in general being better defined, more work remains [4].

The MLSC aims to support and incentivize translational project teams developing novel solutions in this area of need. The Center’s Women’s Health Initiative strives to turn the tide against the severe lack of organized capital and incentives around a coordinated Women’s Health approach.

With continued strategic investment in this area, Massachusetts is poised to become the leader in the Women’s Health space. 

Program Overview

The MLSC Women’s Health Initiative is a bold funding program launched in 2019 designed to close critical gaps in scientific understanding and clinical care for the most pressing and under-researched conditions that affect women solely, disproportionately, or differently. Despite their impact on millions of lives, many of these conditions remain underfunded and poorly understood. This initiative seeks to change that.

Through a rotating focus on specific disease areas, the initiative ensures that a broad spectrum of women’s health topics are addressed over time. For the current cycle, the spotlight is on Pregnancy-Induced Hypertension and Perimenopause/Menopause—two prevalent but neglected areas in biomedical research.

At the heart of the program is a pillar-based research model designed to foster innovation through collaboration. Each disease area is explored across four integrated pillars ensuring a comprehensive, translational approach:

AI and Data Science
Harnessing the power of artificial intelligence, predictive modeling, and big data to identify patterns, improve diagnosis, and uncover new research questions. 

Disease Biology 
Investigating the fundamental mechanisms of disease, including hormonal, genetic, and molecular drivers, to build a foundation for targeted therapies. 

Research and Development 
Advancing preclinical and translational research aimed at developing novel diagnostics, interventions, and therapeutic strategies. 

Clinical Adoption
Bridging research and practice by identifying pathways to integrate discoveries into clinical settings and improve patient outcomes. 

Approximately $3 million in capital funding is available for each disease focus area (up to $6 million in total funding). Awards will support collaborative Massachusetts-based research across these domains. 

Application Process

August 2025
November 2025
November 2025
March 2026
May 2026
July 2026
Application Period Begins
Application
Due
External Review Period Begin
Review Period
Ends
Award
Notification
Project
Begins

Disease Focus Areas

Despite their prevalence and profound impact on quality of life, pregnancy-induced hypertension and perimenopause/menopause remain vastly under-researched and poorly understood. This round’s disease focus areas aim to reverse that trend by investing in targeted science, coordinated strategy, and sustained collaboration. Bringing together these four pillars will create meaningful steps forward in these target fields. 

Pregnancy-Induced Hypertension

Including conditions such as gestational hypertension, preeclampsia, and postpartum preeclampsia, this area seeks to uncover the causes, predictive markers, and optimal interventions for hypertension during pregnancy—conditions that carry serious risks for both parent and child. 

Perimenopause & Menopause 

This research track focuses on the biological transition women experience in midlife, including its impact on cardiovascular, cognitive, and metabolic health—an area historically underfunded and underserved in biomedical research. 

Collaborative Team Model

Applicants will join one of the four pillar-based research teams within their disease focus area. These interdisciplinary teams will work in a coordinated fashion to accelerate understanding, innovation, and implementation—ensuring that progress in one area informs and amplifies others. Although grants are awarded directly to institutions, funded projects are not isolated efforts—they are part of a coordinated ecosystem.

To promote synergy and maximize scientific return, projects within each pillar will actively engage through structured collaboration. This includes:

This structure ensures that progress in one area informs and amplifies efforts across the entire research landscape—from lab bench to clinic. By breaking down silos and uniting multidisciplinary teams, the MLSC Women’s Health Initiative aims to deliver meaningful and lasting advances in women’s health.

Upcoming Info Sessions

Upcoming Teaming Meetings

The MLSC will host virtual Teaming Meetings that aim to connect researchers, clinicians, and public health leaders from Massachusetts-based not-for-profit research institutions. These events are geared towards the creation of collaborative teams developing innovative approaches to address this round’s disease focus areas across four key pillars. Participants will also learn about the Women’s Health Initiative and upcoming funding opportunities.

Become a Sponsor

Companies that are interested in becoming a sponsor should contact the MLSC staff to discuss further. Please contact WomensHealth@masslifesciences.com

Eligibility and Requirements

Eligible applicants must meet the following criteria:

For this solicitation, the MLSC is particularly interested in supporting the following applications from applicants that meet these eligibility parameters:

Note: Industry sponsors of this program will receive access to the data and information resulting from research by Awardees as well as a non-exclusive, worldwide royalty-free license, with the right to sublicense to its affiliates, to any Intellectual Property resulting from the research by Awardees for internal research purposes only. Industry sponsors may negotiate other Intellectual Property and corporate ownership rights and/or licenses with Awardee independently of the Women’s Health Initiative. See the Deliverables, Confidentiality, and General Conditions for more information.

Program Resources

Search our D.A.T.A. repository for the datasets, algorithms, and codebases generated with MLSC funds made publicly available.

Upcoming Team Meetings

Impact on the Ecosystem

The MLSC has deployed more than $19 million across 60 projects in collaboration with 15 companies, fostering advancements in translational research. Together, we can reshape the future of women’s health. 

Learn more about past awardees of programs under the MLSC Women’s Health Initiative here: First Look, Women’s Health Innovation, Women’s health Collaboration.

The MLSC has deployed more than $19 million across 60 projects in collaboration with 15 companies, fostering advancements in translational research.

$ 0 Million

invested by the MLSC to support

0 Projects
$ 0 Million

in follow-on funding received

References:
[1] Estimates of Funding for Various Research, Condition, and Disease Categories. NIH RePORT. 2022. https://report.nih.gov/funding/categorical-spending#/
[2] Mirin, A. Gender Disparity in the Funding of Diseases by the U.S. National Institutes of Health. Journal of Women’s Health 2021 30:7, 956-963
[3] Tharpe, N. Adverse drug reactions in women’s health care. J Midwifery Womens Health. 2011 56(3):205-13. PMID: 21535369.
[4] Vasquez-Avila, K. Addressing the critical role of gender identity and sex in the planning, analysis, and conduct of clinical trials. Princ Pract Clin Res. 2021;7(2):59-62. PMID: 34532571.

Connect with us to learn more

If you have questions regarding the application process, e-mail WomensHealth@masslifesciences.com  with “Women’s Health Initiative” in the subject line.

Other Programs

Solid Swoop 01 scaled 1

Hear from the Heart of the Hub

Sign up for The Beat our weekly newsletter.

  • This field is for validation purposes and should be left unchanged.
Women’s Health Collaboration Program

Women’s Health Collaboration Program

Hero Swoop Purple 02

The application period will run from Aug. 5 – Nov. 21, 2025 at 1 p.m. EST.

Program Overview

The Women’s Health Collaboration Program is part of the MLSC’s Accelerating Research through Collaboration (ARC) Awards. This program supports collaborative projects that aim to improve the discovery, technical innovation, and/or analysis of datasets to answer pressing life science questions around women’s health. It incentivizes translational projects that develop novel solutions to treat conditions that solely or disproportionately affect women or have a different presentation between genders.

Application Process

August 2025
November 2025
November 2025
March 2026
May 2026
July 2026
Application Period Begins
Application
Due
External Review Period Begin
Review Period
Ends
Award
Notification
Project
Begins

Eligibility and Requirements

Project teams are to be comprised of not-for-profit applicants collaborating with at least one for-profit Massachusetts life science company. All not-for-profit applicants must be a Massachusetts legal entity such as an academic/research institution, a hospital engaged in research, a business incubator or accelerator, or other not-for-profit entity eligible for capital funding from the Commonwealth of Massachusetts. Institutions that are exclusively health care providers and/or requests for the purchase of equipment associated with standard healthcare delivery would not be eligible for capital funding.

Applications must be submitted online. The MLSC staff will conduct an initial screening for application completeness and then submit applications to a panel of external experts for review. Applicants may receive invitations to present their proposals to address questions or provide clarification. The MLSC will provide final recommendations to its Board of Directors for approval. 

Program Resources

Please note that the submission system only allows one active application per grant program at a time for each user account. It is possible to have an active application across multiple programs, as well as submit applications for the same program sequentially.

Corner Splash 01 scaled 1 1
CellCorners Red

Impact on the Ecosystem

Massachusetts recognizes there has been a lack of development in novel solutions to treat conditions that solely or disproportionately affect women or have a different presentation between genders. This impacts not only patients, but also employers and the healthcare system. The consequences are profound, with women more likely to have adverse drug reactions than men, and the lack of effective therapies results in reduced quality of life. The Massachusetts Life Sciences Center aims to support and incentivize translational project teams developing novel solutions in this area of need. Over the past six years, the MLSC has awarded $10 million in capital funding through the Women’s Health Collaboration program.

Learn more about the 202020212022, 2023, and 2024 Women’s Health awardees, including the principal investigator, industry partners, and the innovative projects.

$ 0 M

in MLSC investments

$ 0 M
Microscope 1

in leveraged academic & industry funding

0

MA non-profit organizations & industry partners

Handshake
$ 0 M

follow-on funding received

Connect with us to learn more

If you have questions regarding the application process, e-mail WomensHealth@masslifesciences.com.

Other Programs

Solid Swoop 01 scaled 1

Hear From the Heart of the Hub

Sign up for The Beat our weekly newsletter

  • This field is for validation purposes and should be left unchanged.
Workforce Development Capital Grant Program

Workforce Development Capital Grant Program

Program Overview

The Massachusetts Life Sciences Center (MLSC) seeks to further the development and expansion of life sciences education and training programs offered by post-secondary academic institutions and non-profit organizations through capital investment in industry-aligned certificate and degree programs. The MLSC Workforce Development Capital Grant Program will award funding of up to $750,000 per project for the purchase and installation of life sciences equipment, renovations, lab furniture, materials, supplies, and/or technology that will enable them to effectively prepare students for high-demand career opportunities in the life sciences.

Through this program, the MLSC is particularly seeking to seed, enhance and/or expand training programs that address critical skills and talent supply gaps facing the state’s life science industry. Such programs include those focused on biomanufacturing, data science, and regulatory affairs occupations, among others, and have at least one industry partnership. Furthermore, the MLSC is committed to increasing diversity, equity, and inclusion within the life sciences workforce and will prioritize investment in programs that serve underrepresented populations.

The application for FY26 grants will be available starting Dec. 16, 2024. The deadline to apply is March 13, 2025 at 5 p.m. EST.

Eligibility & Evaluation

Applicants must be a Massachusetts legally organized not-for-profit college, university, or organization delivering post-secondary life sciences training.

Funding must be requested for equipment, supplies, materials, technology, and/or renovations to support training that prepares students with skills needed for life sciences careers. Programs must have a focus on skills training for high-demand occupations within the life sciences sector, including but not limited to biomanufacturing, regulatory affairs, data science, facilities management, quality control and quality assurance. The “life sciences” are defined in the MLSC’s enabling legislation as “advanced and applied sciences that expand the understanding of human physiology and have the potential to lead to medical advances or therapeutic applications.”

The MLSC is interested in supporting applicants that will further its goal of developing a skilled workforce suitable for employment in the life sciences, particularly in high-demand occupations. Successful proposals will explain how the requested equipment and supplies will create learning opportunities that are aligned with the needs of the life sciences industry.

Please refer to the Solicitation posted below for more information.

Resources

Solicitation

Program Handout

Application
Applicants are required to create an account prior to accessing the application. If you already have an account, please log in to begin the application.

Impact on the Ecosystem

New state-of-the-art facilities outfitted with industry-standard equipment are now available in all regions of Massachusetts following a decade of strategic investment. The MLSC previously awarded nearly $200 million to 55 colleges and universities to support the construction, renovation, and/or outfitting of life sciences classrooms, labs, and training facilities. More than 120 grants have enabled higher education institutions to train students in first-rate laboratories and provide them with skillsets that meet the needs of their region’s life sciences employers.

Connect with us to Learn More

If you have any questions regarding the application process, e-mail: mlsccapital@masslifesciences.com.

Novel Therapeutics Delivery

Novel Therapeutics Delivery

Program Overview

The Novel Therapeutics Delivery program is part of the MLSC’s Accelerating Research through Collaboration (ARC) Awards. This program fosters the development of novel technologies and techniques for the delivery of existing or innovative therapies by working at the intersection of engineering, biology, chemistry, and medicine. Specifically, it strives to capitalize and incentivize translational projects to address complex challenges in “therapeutic” delivery – from biomanufacturing, to targeted delivery, to biomaterials and more.

Up to $5 million capital dollars are available for the current program round, with each award anticipated to be up to $750,000 to support equipment and other capital expenses at not-for-profit partners.

The application period will run from Aug. 5 – Nov. 21, 2025 at 1 p.m. EST.

Eligibility & Evaluation

Eligibility criteria include multiple factors, such as applicants must be a Massachusetts legally organized “not-for-profit” entity such as an academic/research institution, a hospital engaged in research, business incubator or accelerator, or other not-for-profit entity that would be eligible for capital funding from the Commonwealth of Massachusetts. Institutions that are exclusively health care providers and/or requests for the purchase of equipment associated with standard healthcare delivery would not be eligible for capital funding.

Please view the full list of eligibility requirements and evaluation process.

Resources

Sample Application

  • Please note that the submission system only allows one active application per grant program at a time for each user account. It is possible to have an active application across multiple programs, as well as submit applications for the same program sequentially.

Post-award deliverables, confidentiality, and general conditions

R.E.D.: Research Equipment Database

D.A.T.A. (Databases, Algorithms, Tools, and Analyses) Repository

Impact on the Ecosystem

Innovative new therapies are dependent on advancements in drug delivery. Increased drug complexity, the rise of biopharmaceuticals, novel therapeutic technologies, bioavailability challenges, and the demand for the demonstration of strong drug performance are all driving unprecedented technology innovation; however, the availability of such therapies is not accelerating at the rate with which technology is advancing. Existing therapies can also benefit from improved delivery methods and devices, increasing patient compliance and improving overall health. Over the past six years, the MLSC has awarded $14.7 million in capital funding through the Novel Therapeutics Delivery program.

Learn more about the 2020, 2021, 2022, 2023, and 2024 Novel Therapeutics Delivery awardees, including the principal investigator, industry partners, and the innovative projects.

Connect with Us to Learn More

If you have any questions regarding the application process, e-mail: DrugDelivery@Masslifesciences.com.

Building Breakthroughs

Building Breakthroughs

Program Overview

The Building Breakthroughs Capital Call was designed to provide grants for capital projects that support biomanufacturing innovation, including improvements to upstream/downstream processing, production of cell and gene therapies, monoclonal antibodies, and small molecules, quality and safety, and storage/stability, in the Commonwealth.

Up to $10 million capital dollars was available for the previous program round, with approximately $750,000 awarded per project to support work and equipment at not-for-profit partners. Project teams comprised not-for-profit applicants collaborating with at least one for-profit Massachusetts life science company to solve some of the most pressing biomanufacturing problems.

Impact on the Ecosystem

Massachusetts recognizes that as new innovative therapeutic modalities are being developed, including cell and gene therapies, a biomanufacturing bottleneck exists keeping therapies from patients. Further, currently marketed products can benefit from biomanufacturing innovation to reduce costs and avoid drug shortages. Massachusetts,  home to hundreds of companies pioneering innovative therapies and treatments, is well poised to lead in developing these critical biomanufacturing innovations.

In May 2019, the MLSC announced $2.82 million in funding through the Building Breakthroughs capital program. The capital program funded four projects led respectively by Worcester Polytechnic Institute (WPI), UMass Lowell, and the Massachusetts Institute of Technology (MIT). Each institution received funding to collaborate with industry stakeholders to take a cross-disciplinary approach to improve the biomanufacturing process for much-needed drugs, therapies, and other treatment pathways for patients around the world.

Since 2016, the MLSC has committed more than $21 million to leverage continued investment to accelerate biomanufacturing innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading manufacturing workforce.

Learn more about our 2019 Building Breakthrough awardees, including the principal investigator, industry partners, and project titles.

Connect with us to Learn More

If you have any questions regarding the application process, e-mail: BuildingBreakthroughs@Masslifesciences.com

Bits to Bytes

Bits to Bytes

Program Overview

The MLSC’s Bits to Bytes program is part of the Accelerating Research through Collaboration (ARC) Awards. This program provides grants for scientific projects that generate and analyze large datasets using Artificial Intelligence (AI) or Machine Learning (ML) to answer pressing life science questions, and to attract and train data scientists in the Commonwealth.

As the leading life sciences ecosystem, Massachusetts recognizes that the role of data sciences in life science innovation has rapidly evolved and has the potential to catalyze that innovation at unprecedented rates. Investment in generating well-annotated datasets and training data scientists for life science research is required to sustain Massachusetts’s global leadership position in life science research and development.

The application period will run from Aug. 5 – Nov. 21, 2025 at 1 p.m. EST.

Eligibility & Evaluation

The MLSC is investing up to $5 million capital dollars to support equipment and other capital expenses at not-for-profit partners. Each award will be approximately $750,000 in funding to solve some of the most pressing life science questions using high throughput approaches generating and analyzing large datasets.

Project teams are to be comprised of not-for-profit applicants collaborating with at least one for-profit Massachusetts life science company. All not-for-profit applicants must be a Massachusetts legal entity such as an academic/research institution, hospital engaged in research, business incubator or accelerator, or other not-for-profit entity that would be eligible for capital funding from the Commonwealth of Massachusetts.

For this solicitation, the MLSC is particularly interested in supporting applicants whose research will lead to significant healthcare advances using data-driven approaches and who will recruit and train data scientists in the life science field. While different areas of translational research have different time horizons, successful proposals will explain a clear path, with executable milestones, that leads to new discoveries in partnership with the company.

Please view the full list of eligibility requirements and evaluation process.

Resources

Sample Application

  • Please note that the submission system only allows one active application per grant program at a time for each user account. It is possible to have an active application across multiple programs, as well as submit applications for the same program sequentially.

Post-award Deliverables, Confidentiality, and General Conditions

R.E.D.: Research Equipment Database

D.A.T.A. (Databases, Algorithms, Tools, and Analyses) Repository

Impact on the Ecosystem

The goal of Bits to Bytes is to employ data analytics and/or machine learning techniques to develop a greater understanding of various medical conditions to develop optimal treatments and improve patient health. Additionally, the MLSC and its partners are committed to a collective goal of attracting, training, and retaining data scientists to the life sciences. Exposing data scientists to careers within the life sciences can encourage the application of their much-needed skill sets to the industry and mission-driven work of the life sciences.

Over the past seven years, the MLSC has awarded $27.6 million in capital funding through the Bits to Bytes program. Approximately, $750,000 in funding per project has gone to 37 data-driven, cross-sector projects focused on imaging, cancer, neuroscience, drug discovery and clinical trial design that develop capital assets, data resources, and novel algorithms to address a myriad of health issues. Additionally, these projects train the next generation of post-doctoral data scientists. The non-profit and industry partners on these projects have contributed more than $45.5 million in funds.

Learn more about our 2019, 2020, 2021, 2022, 2023, and 2024 Bits to Bytes awardees, including the principal investigator, industry partners, and the innovative projects.

Connect with us to Learn More

If you have any questions regarding the application process, e-mail: BitsToBytes@Masslifesciences.com

 

MLSC Brandmark scaled 1

Hear from the Heart of the Hub